Biocon, Mylan launch cancer drug in US market
Posted by
www.biotecnika.org
Ogivri, available in a 420mg multi-dose vial and a 150mg single-dose
vial, will be used for treatment of all types of breast cancer and
metastatic stomach cancer (gastric or gastroesophageal junction
adenocarcinoma).
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocon-mylan-launch-cancer-drug-in-us-market/articleshow/72335007.cms
Subscribe to:
Post Comments (Atom)
Post a Comment